GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eisai Co Ltd (OTCPK:ESALF) » Definitions » Cyclically Adjusted PS Ratio

Eisai Co (Eisai Co) Cyclically Adjusted PS Ratio : 0.87 (As of May. 21, 2024)


View and export this data going back to . Start your Free Trial

What is Eisai Co Cyclically Adjusted PS Ratio?

As of today (2024-05-21), Eisai Co's current share price is $42.85. Eisai Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $49.47. Eisai Co's Cyclically Adjusted PS Ratio for today is 0.87.

The historical rank and industry rank for Eisai Co's Cyclically Adjusted PS Ratio or its related term are showing as below:

ESALF' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.64   Med: 0.91   Max: 1.54
Current: 0.9

During the past years, Eisai Co's highest Cyclically Adjusted PS Ratio was 1.54. The lowest was 0.64. And the median was 0.91.

ESALF's Cyclically Adjusted PS Ratio is ranked better than
73.92% of 744 companies
in the Drug Manufacturers industry
Industry Median: 2.135 vs ESALF: 0.90

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Eisai Co's adjusted revenue per share data for the three months ended in Mar. 2024 was $4.434. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $49.47 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Eisai Co Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Eisai Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eisai Co Cyclically Adjusted PS Ratio Chart

Eisai Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.98 0.95 0.75 0.98 0.84

Eisai Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.98 1.29 1.09 0.94 0.84

Competitive Comparison of Eisai Co's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eisai Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eisai Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Eisai Co's Cyclically Adjusted PS Ratio falls into.



Eisai Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Eisai Co's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=42.85/49.47
=0.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eisai Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Eisai Co's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=4.434/107.2000*107.2000
=4.434

Current CPI (Mar. 2024) = 107.2000.

Eisai Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 18.224 98.000 19.935
201409 17.706 98.500 19.270
201412 16.316 97.900 17.866
201503 16.236 97.900 17.778
201506 15.719 98.400 17.125
201509 15.840 98.500 17.239
201512 17.329 98.100 18.936
201603 15.011 97.900 16.437
201606 18.172 98.100 19.858
201609 18.242 98.000 19.955
201612 16.773 98.400 18.273
201703 16.061 98.100 17.551
201706 17.861 98.500 19.439
201709 18.053 98.800 19.588
201712 19.132 99.400 20.633
201803 21.121 99.200 22.824
201806 19.438 99.200 21.006
201809 19.524 99.900 20.951
201812 19.539 99.700 21.009
201903 22.019 99.700 23.675
201906 19.882 99.800 21.356
201909 18.852 100.100 20.189
201912 23.891 100.500 25.484
202003 27.127 100.300 28.993
202006 21.472 99.900 23.041
202009 20.012 99.900 21.474
202012 24.367 99.300 26.306
202103 18.945 99.900 20.329
202106 6.301 99.500 6.789
202109 20.700 100.100 22.168
202112 6.220 100.100 6.661
202203 5.615 101.100 5.954
202206 4.796 101.800 5.050
202209 4.243 103.100 4.412
202212 4.848 104.100 4.992
202303 5.170 104.400 5.309
202306 4.859 105.200 4.951
202309 4.165 106.200 4.204
202312 4.303 106.800 4.319
202403 4.434 107.200 4.434

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eisai Co  (OTCPK:ESALF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Eisai Co Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Eisai Co's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Eisai Co (Eisai Co) Business Description

Traded in Other Exchanges
Address
4-6-10 Koishikawa, Bunkyo-ku, Tokyo, JPN, 112-8088
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.